Retigabine for partial onset seizures

Expert Review of Neurotherapeutics

Volumn 12, Issue 5, 2012, Pages 509-517

  Rheims, Sylvain ^a,b   Ryvlin, Philippe ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

Author keywords

antiepileptic; epilepsy; ezogabine; partial seizures; retigabine

Indexed keywords

POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; RETIGABINE;

AREA UNDER THE CURVE; ASTHENIA; CONFIDENCE INTERVAL; CONFUSION; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTOGENESIS; EUROPE; FOCAL EPILEPSY; GENE MUTATION; GOVERNMENT; HEADACHE; HEART RHYTHM; HUMAN; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOLECULAR WEIGHT; NAUSEA; NONHUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SOMNOLENCE; TREMOR; UNITED STATES; URINE RETENTION; VERTIGO;

ANIMALS; ANTICONVULSANTS; CARBAMATES; DISEASE MODELS, ANIMAL; EPILEPSIES, PARTIAL; HUMANS; PHENYLENEDIAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84860569739     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.33     Document Type: Review

References (41)

1. Forsgren L, Hesdorffer D. Epidemiology and prognosis of epilepsy. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 21-31 (2009)
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34(3), 453-468 (1993)
3. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 10(5), 446-456 (2011)
4. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial. Lancet 369(9566), 1000-1015 (2007)
5. Brodie M, Barry SJ, Bamagous G, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Epilepsia 52(Suppl. 6), 10 (2011)
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314-319 (2000)
7. Hermann B, Seidenberg M, Jones J. The neurobehavioural comorbidities of epilepsy: Can a natural history be developed? Lancet Neurol. 7(2), 151-160 (2008)
8. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: A population-based case-control study. Lancet Neurol. 6(8), 693-698 (2007)
9. Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: Current knowledge and future directions. Lancet Neurol. 7(11), 1021-1031 (2008)
10. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol. 81, 85-110 (2007)
11. Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 10(2), 173-186 (2011)
12. Mansbach H, Baulac M. Retigabine. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 637-646 (2009)
13. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 58(2), 253-262 (2000)
14. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 58(3), 591-600 (2000)
15. Marrion NV. Control of M-current. Annu. Rev. Physiol. 59, 483-504 (1997)
16. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov. 8(12), 982-1001 (2009)
17. Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. 18(1), 25-29 (1998)
18. Wang HS, Pan Z, Shi W et al. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 282(5395), 1890-1893 (1998)
19. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 67(4), 1009-1017 (2005)
20. Rostock A, Tober C, Rundfeldt C et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23(3), 211-223 (1996)
21. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 303(3), 163-169 (1996)
22. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and anti-ictogenic effects of retigabine under conditions of rapid kindling: An ontogenic study. Epilepsia 49(10), 1777-1786 (2008)
23. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res. 83(1), 1-43 (2009)
24. Ferron GM, Paul J, Fruncillo R et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J. Clin. Pharmacol. 42(2), 175-182 (2002)
25. Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br. J. Clin. Pharmacol. 56(1), 39-45 (2003)
26. Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 58(12), 795-802 (2003)
27. Hermann R, Ferron GM, Erb K et al. Effects of age and sex on the disposition of retigabine. Clin. Pharmacol. Ther. 73(1), 61-70 (2003)
28. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68(15), 1197-1204 (2007)
29. Brodie MJ, Lerche H, Gil-Nagel A et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75(20), 1817-1824 (2010)
30. French JA, Abou-Khalil BW, Leroy RF et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76(18), 1555-1563 (2011)
31. Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-Analysis. Epilepsia 52(2), 219-233 (2011)
32. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48(7), 1303-1307 (2007)
33. Burdette DE, Porter RJ, Lee WJK, Hall S, DeRossett SE. Long-term maintenance of efficacy with ezogabine (retigabine) 600-1200 mg/day: An assessment of three open-label extension studies over 12 months. Neurology 76(9), A376-A377 (2011)
34. Abou-Khalil B, Brodie M, Shaikh S, Lee WJK, Hall S, VanLandingham KE. Seizure-free rates in patients receiving long-term open-label ezogabine (retigabine) 600-1200 mg/day. Neurology 76(9), A289-A289 (2011)
35. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol. 62(4), 382-389 (2007)
36. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J. Neurosci. 21(15), 5535-5545 (2001)
37. Brickel N, Hammond J, Viejo A, VanLandingham KE, Derossett SE. Cardiac safety and rates of sudden unexplained death in patients with partial-onset epilepsy treated with ezogabine (retigabine). Neurology 76(9), A616-A616 (2011)
38. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: Systematic review and meta-Analysis. Epilepsia 51(1), 7-26 (2010)
39. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: A meta-Analysis of placebo-controlled randomised trials. Lancet Neurol. 10(11), 961-968 (2011)
40. Ravizza T, Lucas SM, Balosso S et al. Inactivation of caspase-1 in rodent brain: A novel anticonvulsive strategy. Epilepsia 47(7), 1160-1168 (2006)
41. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 51(1), 27-36 (2010)